Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

48.25 -0.86 (-1.75%)
Official Closing Price Updated: 7:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly
Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position? 
Via Investor's Business Daily
Veru's Enobosarm Shows Muscle In Wegovy Combo Trial
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Candidate for Value Investors
NOVO-NORDISK (NYSE:NVO) offers strong profitability, solid growth, and reasonable valuation, making it a compelling choice for value investors. Its financial health and industry-leading margins add... 
Via Chartmill
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?
Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Surprising Stocks That Have More Than Doubled in 2025
Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted. 
Via The Motley Fool
Topics Government
Why Novo Nordisk Stock Just Popped
President Trump has good news for Novo Nordisk investors, and more may be on the way. 
Via The Motley Fool
Topics Government World Trade
"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy."
Via The Motley Fool
Topics Earnings Economy World Trade
8 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Analysts Think These Stocks Could More Than Double in Value
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well. 
Via MarketBeat
Topics World Trade
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide... 
Via Stocktwits
Novo Nordisk To Sell Wegovy For $199 A Month As Compounding Ban Nears: Retail’s Bullish
The offer will be valid through June 30 and aims to encourage patients who previously used compounded versions of the drug to move to Wegovy. 
Via Stocktwits
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Via The Motley Fool
Wegovy, Zepbound Just Got Cheaper: Cigna Sets $200 Monthly Limit For Weight-Loss Drug Users
Cigna’s Evernorth has reached agreements with Eli Lilly and Novo Nordisk to reduce prices for GLP-1 weight-loss drugs Wegovy and Zepbound 
Via Stocktwits
Best Healthcare Stocks: Eli Lilly vs. Novo Nordisk
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why Novo Nordisk Stock Popped on Tuesday
If you can't beat Novo Nordisk, maybe you should join 'em? 
Via The Motley Fool
2 Fantastic Beaten-Down Growth Stocks Down 40% and 45% to Buy
These two stocks are poised for near-term and long-term upside. 
Via The Motley Fool
The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants... 
Via Benzinga
MarketBeat Week in Review – 05/12 - 05/16
Stocks had a strong week on a potential U.S.-China trade deal and cooler inflation data, but volatility may remain as investors shift focus to tax cuts 
Via MarketBeat
Topics Artificial Intelligence Economy Government
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Technical Breakout Potential
NOVO-NORDISK (NYSE:NVO) is a strong growth stock with solid fundamentals and a promising technical setup, offering potential for a breakout. 
Via Chartmill
On Holding on Fire
A consumer goods company hit 40% yearly revenue growth. In this environment? 
Via The Motley Fool
Topics Bonds Government
3 Stocks That Will Profit From Trump's Drug Price Cut
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
Why Novo Nordisk Stock Just Slipped
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price. 
Via The Motley Fool
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. 
Via Investor's Business Daily
Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains optimistic amid mixed signals. 
Via Benzinga
Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes
The company said it would announce the next CEO in “due course,” but did not provide a more definite timeline. 
Via Stocktwits
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
Via The Motley Fool
Is It Time to Buy the Dip in Novo Nordisk Stock?
Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing 
Via MarketBeat
Topics Government
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.